Skip to main content
. 2012 Dec 10;31(3):314–320. doi: 10.1200/JCO.2012.42.4101

Fig 1.

Fig 1.

Progression-free survival (PFS) and overall survival (OS) of 90 eligible patients with advanced-stage follicular non-Hodgkin lymphoma treated with six cycles of cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy followed by tositumomab/131I-tositumomab on Southwest Oncology Group protocol S9911. FU, follow-up.